Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (October 2019)
23 slides from Nemaura Medical's investor presentation, Oct 15, 2019
Slide 1: Corporate Presentation October 2019
Corporate Presentation October 2019 NASDAQ: NMRD
Slide 2: Forward-Looking Statements
Forward - Looking Statements • This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms
Slide 3: Our Mission
Our Mission • By utilizing the world’s first CE Mark approved Non - invasive CGM (continuous glucose monitoring) product, SugarBEAT ®, we aspire to combine our SELF MONITORING/WEARABLE platform, with one - on - one COACHING (independently clinically proven to enhance the impact of diabetes managemen
Slide 4: Investment Highlights
Investment Highlights x World’s first non - invasive CGM (continuous glucose monitor) SugarBEAT ® , targeting $179B+ Global opportunity: • Digital health sector comprising $69B+ type II diabetic market 1 • $50B+ pre - diabetic market 2 • Wearable health - tech sector comprising $60B+ weight loss & w
Slide 5: Our Offering
Our Offering 5 • We are poised to disrupt the multi - billon dollar glucose trending and diabetes management space • SugarBEAT ® is the World’s first non - invasive CGM (Continuous Glucose Monitor) where the sensor sits on top of the skin. Does not require needles and does not puncture the skin to i
Slide 6: How SugarBEAT Works
How SugarBEAT ® Works • A small transmitter device and an adhesive patch with a sensor sits on top of the skin, typically on the upper arm. • The system painlessly draws small amounts of glucose molecules out of the interstitial fluid just below the top layer of skin into a chamber within the patch.
Slide 7: SugarBEAT Competitive Advantages
SugarBEAT ® Competitive Advantages Safe - MARD 12.4% with one calibration per day Insulin - dosing decisions with adjunctive finger stick Predictive alerts and real - time CGM capabilities On average 25 minute warm - up period Hypo - allergenic - Daily new patch location No skin penetration by senso
Slide 8: Potentially game-changing moment for big data in the health industry
Potentially game - changing moment for big data in the health industry The Value of Medical Data Realtime Mobile technology has been one of the largest contributors to big data for the past several years. Proliferation of mobile phones, the implementation of app - enabled smart phones, and now the g
Slide 9: Nemaura vs Livongo
Nemaura vs Livongo ® The technical difference! Starts with a supporting approved medical device . The Trends In Mobile Healthcare • What we are seeing is a total shift towards digital medical care. The records are more often kept electronically, there are more opportunities for remote patient monito
Slide 10: Commercial Strategy
Commercial Strategy: Priority 1: Subscription based service • A monthly subscription to receive a set number of sensors each month and the app which will allow the user to share their data with family and care givers, and be able to monitor their glucose profile relative to lifestyle interventions a
Slide 11: Nemaura Medical Launch Strategy
N EMAURA M EDICAL L AUNCH S TRATEGY • G ERMANY : M ARKET O PPORTUNITY OF $3 - 5B • UK: M ARKET O PPORTUNITY OF $2 - 4B • I RELAND : M ARKET O PPORTUNITY OF $1B • Nemaura's product offering is being led by their Vice President of Strategy and Strategic Alliances, Dr Fred Shaebsdau . • From September
Slide 12: UK subscriber potential and NHS programs
The number of people that could benefit from SugarBEAT® is significant but even in a scenario where this was only rolled out ac ross staff considered to be high value assets to the 100 biggest companies in the UK, we forecast this having the potential of achieving over 200,000 su bscribers in the UK
Slide 13: SugarBEAT Key Milestones
SugarBEAT ® Key Milestones 13 1Q 2016: SugarBEAT ® received CE Mark in Europe on Predecessor Product (wristwatch) 4Q 2017: Successful 525 patient trial completed in Europe for SugarBEAT ® 1Q 2018: NMRD Lists on Nasdaq 2Q 2018: SugarBEAT ® began FDA clinical program 3Q 2018: Published interim FDA cli
Slide 14: Current Product Pipeline
Current Product Pipeline NASDAQ: NMRD 14 Product Key Features Market SugarBEAT ® Gen II • Include pediatric cover • Improved accuracy (MARD) • Longer patch wear time • Include Gestational use • Type II Diabetics • Pre - Diabetics • Wearable Health - Tech • Pregnancy Continuous Lactate Monitoring • W
Slide 15: Future Product Pipeline
Future Product Pipeline 15 Product Uses Diagnostics Alcohol Monitoring Support personal health goals, and provide warnings prior to driving, and provide physicians with individual drinking habits Prevention of progression to alcohol related diseases. Prostaglandin Monitoring Screening for inflammato
Slide 16: The Management Team
THE MANAGEMENT TEAM Dr. Faz Chowdhury Chief Executive Officer Dr. Chowdhury has served as CEO and chair of the board of Nemaura Medical since formation in December 2013. He is sole inventor on more than 100 granted and pending patents across over 20 technology platforms within the medical device and
Slide 17: Key Statistics
Key Statistics • Ticker: NMRD • Exchange: NASDAQ CM • Share price: $0.70* • Common Shares Outstanding: 208.0M* • Market Capitalization: $146.1M* • Options and Warrants: 11.9M* • (10M @ $0.50 & 1.9M @ $1.04)* • Total Potential shares outstanding: 221.7M • Fiscal year end March 31 st 2019 • Insider ow
Slide 18: Investment Opportunity Summary
Investment Opportunity Summary Nemaura Medical aims to dominate the global diabetes markets for putting Type 2 diabetes into remission, using the SugarBEAT ® device and digital healthcare platform. • Within 5 years the company aims to lead in the wearables market and self - management of medical con
Slide 19: Appendices
Appendices 19 NASDAQ: NMRD
Slide 20: Manufacturing The Device And Sensors
Manufacturing The Device And Sensors • Transmitter device and charging station • All manufactured in the UK and can be readily scaled to by adding multiple lines to what is a linear operation. • Disposable skin adhesive and ancillary disposable parts • All manufactured in the UK and can be readily s
Slide 21: SugarBEAT Clinical Data
SugarBEAT ® Clinical Data • Completed clinical studies to support FDA submission • The clinical studies used were split between Type I and Type II diabetics • Consisted of 75 patients over 225 patient days • Generated over 12,000 paired data points, with blood samples taken via catheter every 15 min
Slide 22: SugarBEAT Regulatory Pathway
SugarBEAT® Regulatory Pathway • U.S. FDA De - Novo 510(k) x Completed clinical studies to support FDA De - Novo 510(k) submission x FDA Approval: target by end of 2020. • European CE Mark x Approval Received at the end of Q2 2019. De - Novo 510(k) • Lower risk (Class II graded medium risk) • Quicker
Slide 23: Intellectual Property
Intellectual Property Building an extensive intellectual property portfolio to position the Company to become a leader in the non - invasive CGM space The Company has over thirty patents (~70% approved and ~30% pending) spanning the following patent families: 1. Sensor related 2. Algorithm and metho
Nemaura Medical — Investor Presentation (October 2019) on 6ix